Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kymera Therapeutics stock

Own Kymera Therapeutics stock in just a few minutes.

Posted

Fact checked

Kymera Therapeutics, Inc is a biotechnology business based in the US. Kymera Therapeutics shares (KYMR) are listed on the NASDAQ and all prices are listed in US Dollars. Kymera Therapeutics employs 64 staff and has a trailing 12-month revenue of around USD$23.1 million.

How to buy shares in Kymera Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Kymera Therapeutics. Find the stock by name or ticker symbol: KYMR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kymera Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kymera Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Kymera Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kymera Therapeutics share price

Use our graph to track the performance of KYMR stocks over time.

Kymera Therapeutics shares at a glance

Information last updated 2020-11-20.
52-week range USD$25.43 - USD$53.49
50-day moving average USD$39.0014
200-day moving average USD$35.2936
Wall St. target price USD$51.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Kymera Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kymera Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kymera Therapeutics financials

Revenue TTM USD$23.1 million
Gross profit TTM USD$-34,224,000
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin -192.45%
Book value N/A
Market capitalisation USD$2.2 billion

TTM: trailing 12 months

Shorting Kymera Therapeutics shares

There are currently 461,322 Kymera Therapeutics shares held short by investors – that's known as Kymera Therapeutics's "short interest". This figure is 1.9% down from 470,219 last month.

There are a few different ways that this level of interest in shorting Kymera Therapeutics shares can be evaluated.

Kymera Therapeutics's "short interest ratio" (SIR)

Kymera Therapeutics's "short interest ratio" (SIR) is the quantity of Kymera Therapeutics shares currently shorted divided by the average quantity of Kymera Therapeutics shares traded daily (recently around 99853.246753247). Kymera Therapeutics's SIR currently stands at 4.62. In other words for every 100,000 Kymera Therapeutics shares traded daily on the market, roughly 4620 shares are currently held short.

However Kymera Therapeutics's short interest can also be evaluated against the total number of Kymera Therapeutics shares, or, against the total number of tradable Kymera Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kymera Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Kymera Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0142% of the tradable shares (for every 100,000 tradable Kymera Therapeutics shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kymera Therapeutics.

Find out more about how you can short Kymera Therapeutics stock.

Kymera Therapeutics share dividends

We're not expecting Kymera Therapeutics to pay a dividend over the next 12 months.

Kymera Therapeutics overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site